Clinical Trial Update: The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating a combination of tislelizumab, anlotinib, S-1, and oxaliplatin for locally advanced adenocarcinoma of the esophagogastric…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Esophagogastric Junction
• Gastroesophageal Junction Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Immunotherapy Gastroesophageal Junction | Phase 2 | Status: NOT_YET_RECRUITING